396 related articles for article (PubMed ID: 20091566)
21. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
[TBL] [Abstract][Full Text] [Related]
22. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
[TBL] [Abstract][Full Text] [Related]
23. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
Sullivan SD; Craxi A; Alberti A; Giuliani G; De Carli C; Wintfeld N; Patel KK; Green J
Pharmacoeconomics; 2004; 22(4):257-65. PubMed ID: 14974875
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological interventions for acute hepatitis C infection.
Kalafateli M; Buzzetti E; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD011644. PubMed ID: 30521693
[TBL] [Abstract][Full Text] [Related]
25. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
26. Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection.
von Wagner M; Hofmann WP; Teuber G; Berg T; Goeser T; Spengler U; Hinrichsen H; Weidenbach H; Gerken G; Manns M; Buggisch P; Herrmann E; Zeuzem S
Hepatology; 2008 Nov; 48(5):1404-11. PubMed ID: 18846541
[TBL] [Abstract][Full Text] [Related]
27. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
Pessôa MG; Cheinquer H; Almeida PR; Silva GF; Lima MP; Paraná R; Lacerda MA; Parise ER; Pernambuco JR; Pedrosa SS; Teixeira R; Sette H; Tatsch F
Ann Hepatol; 2012; 11(1):52-61. PubMed ID: 22166561
[TBL] [Abstract][Full Text] [Related]
28. Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy.
Bräu N
J Antimicrob Chemother; 2005 Dec; 56(6):991-5. PubMed ID: 16308419
[TBL] [Abstract][Full Text] [Related]
29. WITHDRAWN: Ribavirin with or without alpha interferon for chronic hepatitis C.
Gluud LL; Krogsgaard K; Gluud C
Cochrane Database Syst Rev; 2007 Jul; 2002(2):CD002234. PubMed ID: 17636700
[TBL] [Abstract][Full Text] [Related]
30. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.
Reddy KR; Zeuzem S; Zoulim F; Weiland O; Horban A; Stanciu C; Villamil FG; Andreone P; George J; Dammers E; Fu M; Kurland D; Lenz O; Ouwerkerk-Mahadevan S; Verbinnen T; Scott J; Jessner W
Lancet Infect Dis; 2015 Jan; 15(1):27-35. PubMed ID: 25482330
[TBL] [Abstract][Full Text] [Related]
31. The treatment of chronic hepatitis C in HIV-infected patients: a meta-analysis.
Kim AI; Dorn A; Bouajram R; Saab S
HIV Med; 2007 Jul; 8(5):312-21. PubMed ID: 17561878
[TBL] [Abstract][Full Text] [Related]
32. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
Ferenci P; Formann E; Laferl H; Gschwantler M; Hackl F; Brunner H; Hubmann R; Datz C; Stauber R; Steindl-Munda P; Kessler HH; Klingler A; Gangl A;
J Hepatol; 2006 Feb; 44(2):275-82. PubMed ID: 16338019
[TBL] [Abstract][Full Text] [Related]
33. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
Labarga P; Barreiro P; da Silva A; Guardiola JM; Rubio R; Aguirrebengoa K; Miralles P; Portu J; Téllez MJ; Morano L; Castro A; Pineda JA; Terrón A; Hernández-Quero J; Mariño A; Ríos MJ; Echeverría S; Asensi V; Vispo E; Soriano V;
J Infect Dis; 2012 Sep; 206(6):961-8. PubMed ID: 22807523
[TBL] [Abstract][Full Text] [Related]
34. Direct-acting antivirals for chronic hepatitis C.
Jakobsen JC; Nielsen EE; Feinberg J; Katakam KK; Fobian K; Hauser G; Poropat G; Djurisic S; Weiss KH; Bjelakovic M; Bjelakovic G; Klingenberg SL; Liu JP; Nikolova D; Koretz RL; Gluud C
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD012143. PubMed ID: 28922704
[TBL] [Abstract][Full Text] [Related]
35. Spotlight on peginterferon-alpha-2a (40KD) in chronic hepatitis C.
Perry CM; Jarvis B
BioDrugs; 2002; 16(3):213-7. PubMed ID: 12102649
[TBL] [Abstract][Full Text] [Related]
36. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
[TBL] [Abstract][Full Text] [Related]
37. Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients.
Crespo M; Sauleda S; Esteban JI; Juarez A; Ribera E; Andreu AL; Falco V; Quer J; Ocaña I; Ruiz I; Buti M; Pahissa A; Esteban R; Guardia J
J Viral Hepat; 2007 Apr; 14(4):228-38. PubMed ID: 17381714
[TBL] [Abstract][Full Text] [Related]
38. Direct-acting antivirals for chronic hepatitis C.
Jakobsen JC; Nielsen EE; Feinberg J; Katakam KK; Fobian K; Hauser G; Poropat G; Djurisic S; Weiss KH; Bjelakovic M; Bjelakovic G; Klingenberg SL; Liu JP; Nikolova D; Koretz RL; Gluud C
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD012143. PubMed ID: 28585310
[TBL] [Abstract][Full Text] [Related]
39. A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients.
Puoti M; Zanini B; Quinzan GP; Ravasio L; Paraninfo G; Santantonio T; Rollo A; Artioli S; Maggiolo F; Zaltron S; Raise E; Mignani E; Resta F; Verucchi G; Pastore G; Suter F; Carosi G;
J Hepatol; 2004 Aug; 41(2):312-8. PubMed ID: 15288482
[TBL] [Abstract][Full Text] [Related]
40. Ribavirin with or without alpha interferon versus no intervention, placebo or alpha interferon for chronic hepatitis C.
Kjaergard LL; Krogsgaard K; Gluud C
Cochrane Database Syst Rev; 2002; (1):CD002234. PubMed ID: 11869633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]